Table 2. Prognostic factors for disease-free survival and overall survival in multivariate analysis.
| Factor | Disease-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|---|
| HR* | 95.0% CI | P# | HR* | 95.0% CI | P# | ||
| Age | (continuous) | 0.96 | 0.72-1.28 | 0.77 | 0.93 | 0.63-1.38 | 0.73 |
| Size | (<2cm vs. 2-5cm) | 1.41 | 0.92-2.14 | 0.11 | 2.22 | 1.10-4.47 | 0.03 |
| (<2cm vs. >5cm) | 1.94 | 1.16-3.26 | 0.012 | 3.03 | 1.35-6.80 | 0.007 | |
| Nodal status | (0 vs. 1-3) | 1.88 | 1.21-2.92 | 0.005 | 1.68 | 0.89-3.20 | 0.11 |
| (0 vs. ≥4) | 5.38 | 3.66-7.91 | <0.001 | 6.24 | 3.66-10.64 | <0.001 | |
| Surgical modality | (Mast. vs. BCS) | 0.56 | 0.21-1.49 | 0.24 | 0.78 | 0.29-2.11 | 0.63 |
| Endocrine therapy | (No vs. Yes) | 1.24 | 0.80-1.94 | 0.34 | 1.98 | 0.99-3.96 | 0.05 |
| Molecular subtype | (luminal-A vs. -B) | 1.35 | 0.91-2.01 | 0.14 | 1.13 | 0.63-2.06 | 0.67 |
| (luminal-A vs. TNBC) | 2.30 | 1.38-3.84 | 0.001 | 3.59 | 1.68-7.66 | 0.001 | |
| (luminal-A vs. HER2+) | 2.32 | 1.30-4.12 | 0.004 | 3.74 | 1.63-8.61 | 0.002 | |
| Time to chemotherapy | (0-4 vs. 4-8 weeks) | 1.14 | 0.83-1.56 | 0.42 | 1.43 | 0.94-2.19 | 0.09 |
| (0-4 vs. >8 weeks) | 1.86 | 1.19-2.90 | 0.006 | 2.02 | 1.10-3.71 | 0.02 | |
Abbreviations: BCS, breast conservative surgery; CI, confidence interval; HR, hazard ratio; MS, mastectomy; TNBC, triple-negative breast cancer
Method for Cox proportional hazards analysis: Enter all the variables.
#Adjusted for all the factors listed in the table.